PapersFlow Research Brief
Chronic Myeloid Leukemia Treatments
Research Guide
What is Chronic Myeloid Leukemia Treatments?
Chronic Myeloid Leukemia Treatments are targeted therapies, primarily tyrosine kinase inhibitors such as Imatinib, Dasatinib, and Nilotinib, that inhibit BCR-ABL tyrosine kinase activity to achieve molecular responses and improve long-term outcomes in CML patients.
The field encompasses 65,587 papers on the efficacy and resistance of tyrosine kinase inhibitors like Imatinib in CML treatment. Research covers molecular mechanisms of resistance, mutation analysis, leukemia stem cells, treatment discontinuation, and outcomes of targeted therapies. Growth rate over the past 5 years is not available in the data.
Topic Hierarchy
Research Sub-Topics
BCR-ABL Kinase Domain Mutations
This sub-topic examines specific point mutations in the BCR-ABL kinase domain, such as T315I, that confer resistance to tyrosine kinase inhibitors in CML patients. Researchers study mutation prevalence, detection methods, and their correlation with treatment failure.
Tyrosine Kinase Inhibitor Resistance Mechanisms
This sub-topic investigates molecular pathways beyond kinase mutations, including BCR-ABL amplification and efflux pump overexpression, leading to TKI resistance in CML. Researchers analyze signaling cascades and epigenetic changes contributing to acquired resistance.
CML Leukemia Stem Cells
This sub-topic focuses on the persistence of quiescent leukemia stem cells in CML that survive TKI therapy and drive relapse. Researchers explore stem cell quiescence markers, niche interactions, and strategies for stem cell eradication.
Treatment-Free Remission in CML
This sub-topic studies criteria, predictors, and outcomes of discontinuing TKIs in deep molecular responders to achieve treatment-free remission. Researchers monitor minimal residual disease and relapse kinetics post-discontinuation.
Second-Generation Tyrosine Kinase Inhibitors
This sub-topic evaluates the efficacy, safety, and switching strategies for Dasatinib and Nilotinib compared to Imatinib in newly diagnosed or resistant CML. Researchers compare molecular response rates and progression-free survival across inhibitors.
Why It Matters
Tyrosine kinase inhibitors have transformed CML management by providing superior hematologic and cytogenetic responses compared to prior therapies. Druker et al. (2001) demonstrated that STI571, later known as Imatinib, showed significant antileukemic activity in CML patients who failed interferon alfa, with evidence of BCR-ABL tyrosine kinase's essential role. O’Brien et al. (2003) reported Imatinib superiority over interferon alfa plus low-dose cytarabine in newly diagnosed chronic-phase CML, reducing progression to accelerated-phase or blast-crisis. These findings support first-line use of Imatinib, enabling sustained responses in advanced cases as confirmed in early cellular studies by Druker et al. (1996).
Reading Guide
Where to Start
"Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia" by Druker et al. (2001), as it provides foundational clinical evidence of Imatinib's antileukemic activity in interferon-failed patients and BCR-ABL's role.
Key Papers Explained
Druker et al. (1996) first showed selective Abl inhibitor effects on BCR-ABL positive cells in "Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells", enabling Druker et al. (2001) to demonstrate clinical efficacy of STI571/Imatinib in "Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia". O’Brien et al. (2003) built on this in "Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia" by confirming Imatinib's superiority as first-line therapy over interferon alfa combinations.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Research emphasizes resistance mechanisms, BCR-ABL mutations, leukemia stem cells, and treatment discontinuation, as reflected in the 65,587-paper cluster. No recent preprints or news in the last 12 months indicate steady focus on long-term targeted therapy outcomes.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | Diagnosis and management of AML in adults: 2017 ELN recommenda... | 2016 | Blood | 5.7K | ✓ |
| 2 | Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyr... | 2001 | New England Journal of... | 5.2K | ✓ |
| 3 | The resurgence of platinum-based cancer chemotherapy | 2007 | Nature reviews. Cancer | 4.6K | ✕ |
| 4 | Efficacy and Safety of Imatinib Mesylate in Advanced Gastroint... | 2002 | New England Journal of... | 4.3K | ✓ |
| 5 | A New Consistent Chromosomal Abnormality in Chronic Myelogenou... | 1973 | Nature | 4.2K | ✕ |
| 6 | Cellular processing of platinum anticancer drugs | 2005 | Nature Reviews Drug Di... | 3.7K | ✕ |
| 7 | Effects of a selective inhibitor of the Abl tyrosine kinase on... | 1996 | Nature Medicine | 3.6K | ✕ |
| 8 | Imatinib Compared with Interferon and Low-Dose Cytarabine for ... | 2003 | New England Journal of... | 3.5K | ✓ |
| 9 | Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Er... | 2005 | PLoS Medicine | 3.5K | ✓ |
| 10 | A unique clonal JAK2 mutation leading to constitutive signalli... | 2005 | Nature | 3.5K | ✕ |
Frequently Asked Questions
What is the role of BCR-ABL tyrosine kinase in CML treatments?
BCR-ABL tyrosine kinase drives CML pathogenesis, and its inhibition by specific inhibitors like STI571 produces antileukemic activity. Druker et al. (2001) showed STI571 was well tolerated with significant effects in interferon-failed CML patients. This confirms BCR-ABL's essential role and supports targeted inhibitor development.
How does Imatinib compare to interferon alfa in newly diagnosed CML?
Imatinib provides superior hematologic and cytogenetic responses, better tolerability, and lower progression risk to accelerated-phase or blast-crisis CML. O’Brien et al. (2003) found it outperformed interferon alfa plus low-dose cytarabine as first-line therapy in chronic-phase CML. These outcomes establish Imatinib as preferred initial treatment.
What evidence supports selective Abl tyrosine kinase inhibitors in BCR-ABL positive cells?
Selective inhibitors of Abl tyrosine kinase suppress growth of BCR-ABL positive cells. Druker et al. (1996) demonstrated this effect in cellular models. The work laid groundwork for clinical BCR-ABL targeted therapies in CML.
What are common mechanisms of resistance in CML treatments?
Resistance to tyrosine kinase inhibitors in CML involves molecular mechanisms like mutations, as studied across 65,587 papers. The cluster addresses BCR-ABL mutation analysis and leukemia stem cells contributing to resistance. These factors guide strategies for overcoming treatment failure.
What outcomes are associated with Imatinib in advanced CML?
Imatinib induces sustained objective responses in advanced CML cases resistant to conventional therapy. Druker et al. (2001) reported significant activity in interferon-failed patients. Long-term molecular responses and treatment discontinuation are key focus areas in the field.
Open Research Questions
- ? How can leukemia stem cells be effectively targeted to prevent CML persistence despite tyrosine kinase inhibitor therapy?
- ? What molecular mechanisms beyond known BCR-ABL mutations drive resistance to second-generation inhibitors like Dasatinib and Nilotinib?
- ? Under what conditions can tyrosine kinase inhibitor treatment be safely discontinued in CML patients achieving deep molecular response?
- ? How do long-term outcomes vary between Imatinib and newer inhibitors in newly diagnosed chronic-phase CML?
Recent Trends
The field maintains 65,587 works with no specified 5-year growth rate, centering on tyrosine kinase inhibitor efficacy, resistance via BCR-ABL mutations, and leukemia stem cells.
No preprints from the last 6 months or news in the past 12 months signal ongoing emphasis on established inhibitors like Imatinib, Dasatinib, and Nilotinib without new disruptions.
Research Chronic Myeloid Leukemia Treatments with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Chronic Myeloid Leukemia Treatments with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers